[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601379":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":11,"centralContacts":36,"locations":42,"responsibleParty":294,"collaborators":11,"id":296,"slug":297,"hasResults":298,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":11,"eligibilityCriteria":301,"healthyVolunteers":298,"sex":302,"minAge":303,"maxAge":11,"enrollmentInfo":304,"targetDuration":11,"studyType":307,"phases":308,"briefSummary":311,"conditions":312,"keywords":321,"overallStatus":45,"whyStopped":11,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":334},{"fullName":5,"class":6},"Terremoto Biosciences Inc.","INDUSTRY",[8,14,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Monotherapy Dose Escalation","EXPERIMENTAL",null,[13],"Drug: TER-2013",{"label":15,"type":10,"description":16,"interventionNames":17},"Combination Therapy Dose Escalation","Dose Escalation of TER-2013 with recommended dose of fulvestrant",[13,18],"Drug: Fulvestrant injection",{"label":20,"type":10,"description":11,"interventionNames":21},"Monotherapy Dose Expansion",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Combination Therapy Dose Expansion","Dose Expansion of TER-2013 with recommended dose of fulvestrant",[13,18],[27,32],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"DRUG","TER-2013","Oral Capsules",[15,23,9,20],{"type":28,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"Fulvestrant injection","Fulvestrant 500 mg Intramuscular Injection",[15,23],[37],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Terremoto Biosciences, Inc. Clinical Trials Central Contact","CONTACT","888-682-1551","clinicaltrials@terremotobio.com",[43,62,73,88,100,110,125,140,155,170,183,198,213,225,238,252,264,279],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-117.97729,34.13945,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":60,"phoneExt":11,"email":61},"Felicia Lewis","626-218-5097","flewis@coh.org",{"facility":63,"status":45,"city":64,"state":47,"zip":65,"country":49,"countryCode":50,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"City of Hope, Irvine","Irvine","92618",{"type":52,"coordinates":67},[68,69],-117.82311,33.66946,{"lat":69,"lon":68},[72],{"name":59,"role":39,"phone":60,"phoneExt":11,"email":61},{"facility":74,"status":45,"city":75,"state":76,"zip":77,"country":49,"countryCode":50,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Florida Cancer Specialists - Lake Nona","Orlando","Florida","32827",{"type":52,"coordinates":79},[80,81],-81.37924,28.53834,{"lat":81,"lon":80},[84],{"name":85,"role":39,"phone":86,"phoneExt":11,"email":87},"Elizabeth Griffith- Gilmore","904-380-2418","elizabeth.griffith@scri.com",{"facility":89,"status":45,"city":90,"state":91,"zip":92,"country":49,"countryCode":50,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"City of Hope, Chicago","Zion","Illinois","60099",{"type":52,"coordinates":94},[95,96],-87.83285,42.44613,{"lat":96,"lon":95},[99],{"name":59,"role":39,"phone":60,"phoneExt":11,"email":61},{"facility":101,"status":45,"city":102,"state":103,"zip":104,"country":49,"countryCode":50,"cosmosGeoPoint":105,"geoPoint":109,"contacts":11},"Massachusetts General Hospital","Boston","Massachusetts","02144",{"type":52,"coordinates":106},[107,108],-71.05977,42.35843,{"lat":108,"lon":107},{"facility":111,"status":45,"city":112,"state":113,"zip":114,"country":49,"countryCode":50,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Mayo Rochester","Rochester","Minnesota","55905",{"type":52,"coordinates":116},[117,118],-92.4699,44.02163,{"lat":118,"lon":117},[121],{"name":122,"role":39,"phone":123,"phoneExt":11,"email":124},"Clinical Research Recruitment","507-284-2511","mayocliniccancerstudies@mayo.edu",{"facility":126,"status":45,"city":127,"state":128,"zip":129,"country":49,"countryCode":50,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Washington Univ. School of Medicine","St Louis","Missouri","63110",{"type":52,"coordinates":131},[132,133],-90.19789,38.62727,{"lat":133,"lon":132},[136],{"name":137,"role":39,"phone":138,"phoneExt":11,"email":139},"Study Coordinator","800-600-3606","enix@wustl.edu",{"facility":141,"status":45,"city":142,"state":143,"zip":144,"country":49,"countryCode":50,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"Nebraska Cancer Specialists","Omaha","Nebraska","68130",{"type":52,"coordinates":146},[147,148],-95.94043,41.25626,{"lat":148,"lon":147},[151],{"name":152,"role":39,"phone":153,"phoneExt":11,"email":154},"Ashley Servais Degenhardt","402-955-2691","aservais@nebraskacancer.com",{"facility":156,"status":45,"city":157,"state":158,"zip":159,"country":49,"countryCode":50,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"Carolina BioOncology Institute","Huntersville","North Carolina","28078",{"type":52,"coordinates":161},[162,163],-80.84285,35.41069,{"lat":163,"lon":162},[166],{"name":167,"role":39,"phone":168,"phoneExt":11,"email":169},"Ryan Allen","704-947-6599","info@carolinabioooncology.org",{"facility":171,"status":45,"city":172,"state":173,"zip":174,"country":49,"countryCode":50,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"UH Cleveland Medical Center","Cleveland","Ohio","44106",{"type":52,"coordinates":176},[177,178],-81.69541,41.4995,{"lat":178,"lon":177},[181],{"name":11,"role":39,"phone":182,"phoneExt":11,"email":11},"833-788-7425",{"facility":184,"status":45,"city":185,"state":186,"zip":187,"country":49,"countryCode":50,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Sarah Cannon Nashville","Nashville","Tennessee","37203",{"type":52,"coordinates":189},[190,191],-86.78444,36.16589,{"lat":191,"lon":190},[194],{"name":195,"role":39,"phone":196,"phoneExt":11,"email":197},"Referral Coordinator","615.329.7274","asksarah@scresearch.net",{"facility":199,"status":45,"city":200,"state":201,"zip":202,"country":49,"countryCode":50,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"NEXT Oncology","Austin","Texas","78229",{"type":52,"coordinates":204},[205,206],-97.74306,30.26715,{"lat":206,"lon":205},[209],{"name":210,"role":39,"phone":211,"phoneExt":11,"email":212},"Recruitment Coordinator","737-610-5200","NXTAUS_Coordinators@nextoncology.com",{"facility":214,"status":45,"city":215,"state":201,"zip":216,"country":49,"countryCode":50,"cosmosGeoPoint":217,"geoPoint":221,"contacts":222},"MD Anderson Cancer Center","Houston","77030",{"type":52,"coordinates":218},[219,220],-95.36327,29.76328,{"lat":220,"lon":219},[223],{"name":11,"role":39,"phone":224,"phoneExt":11,"email":11},"877-589-0209",{"facility":226,"status":45,"city":227,"state":201,"zip":202,"country":49,"countryCode":50,"cosmosGeoPoint":228,"geoPoint":232,"contacts":233},"START Center for Cancer Research","San Antonio",{"type":52,"coordinates":229},[230,231],-98.49363,29.42412,{"lat":231,"lon":230},[234],{"name":235,"role":39,"phone":236,"phoneExt":11,"email":237},"Isabel Jimenez","210-593-5265","isabel.jimenez@startresearch.com",{"facility":226,"status":45,"city":239,"state":240,"zip":241,"country":49,"countryCode":50,"cosmosGeoPoint":242,"geoPoint":246,"contacts":247},"West Valley City","Utah","84119",{"type":52,"coordinates":243},[244,245],-112.00105,40.69161,{"lat":245,"lon":244},[248],{"name":249,"role":39,"phone":250,"phoneExt":11,"email":251},"Marie Assay","801-907-4770","marie.asay@startresearch.com",{"facility":199,"status":45,"city":253,"state":254,"zip":255,"country":49,"countryCode":50,"cosmosGeoPoint":256,"geoPoint":260,"contacts":261},"Fairfax","Virginia","22031",{"type":52,"coordinates":257},[258,259],-77.30637,38.84622,{"lat":259,"lon":258},[262],{"name":195,"role":39,"phone":263,"phoneExt":11,"email":212},"(703) 783-4518",{"facility":265,"status":45,"city":266,"state":267,"zip":268,"country":49,"countryCode":50,"cosmosGeoPoint":269,"geoPoint":273,"contacts":274},"Froedtert & MCW Cancer Center","Milwaukee","Wisconsin","53226",{"type":52,"coordinates":270},[271,272],-87.90647,43.0389,{"lat":272,"lon":271},[275],{"name":276,"role":39,"phone":277,"phoneExt":11,"email":278},"John Charlson","414-805-8900","jcharlson@mcw.edu",{"facility":280,"status":45,"city":281,"state":11,"zip":282,"country":283,"countryCode":284,"cosmosGeoPoint":285,"geoPoint":289,"contacts":290},"PanOncology Trials","San Juan","00935","Puerto Rico","PR",{"type":52,"coordinates":286},[287,288],-66.10572,18.46633,{"lat":288,"lon":287},[291],{"name":137,"role":39,"phone":11,"phoneExt":292,"email":293},"787-407-3333","info@panoncologytrials.com",{"type":295,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100601379","phase-1-a-phase-12-trial-of-ter-2013-in-patients-with-solid-tumors-harboring-aktpi3kpten-pathway-alterations-100601379",false,"NCT07109726","A Phase 1\u002F2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT\u002FPI3K\u002FPTEN Pathway Alterations","Key Inclusion Criteria\n\n* Metastatic or locally advanced, unresectable disease\n* No available treatment with curative intent\n* Presence of lesions to be evaluated per RECIST v1.1:\n\n  a. Dose Escalation: measurable or evaluable disease b. Cohort Expansion: measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ function\n* Advanced solid tumor malignancy harboring an eligible AKT\u002FPI3K\u002FPTEN pathway alteration detected by a sponsor approved test\n\nKey Inclusion Criteria for TER-2013 monotherapy arms:\n\n* Histologically confirmed diagnosis of:\n\n  a. \\[For TER-2013 dose escalation\\]: solid tumor malignancy b. \\[For TER-2013 cohort expansion\\]: i. Cohort 1: ovarian cancer, cervical cancer, or squamous cell carcinoma of the head and neck, lung, or esophagus ii. Cohort 2: endometrial adenocarcinoma\n* Prior therapy:\n\n  1. \\[For TER-2013 dose escalation\\]: Received standard therapies appropriate for their tumor type and stage, unless contraindicated, intolerable, or patient refused\n  2. \\[For TER-2013 cohort expansion\\]: No more than 3 prior lines of treatment in the advanced setting\n\n     Key Inclusion Criteria for TER-2013 and fulvestrant combination arms\n* Histologically confirmed diagnosis of:\n\n  a. \\[For TER-2013 + fulvestrant dose escalation\\]: HR+\u002FHER2- advanced unresectable or metastatic breast cancer b. \\[For TER-2013 + fulvestrant cohort expansion\\]: i. Received treatment with an AI containing regimen (single agent or in combination) ii. No more than 3 prior lines of treatment in the advanced unresectable or metastatic setting\n* Prior Therapy:\n\n  a. \\[For TER-2013 + fulvestrant dose escalation\\]: Received treatment with an AI containing regimen (single agent or in combination) b. \\[For TER-2013 + fulvestrant cohort expansion\\]: i. Received treatment with an AI containing regimen (single agent or in combination) ii. No more than 3 prior lines of treatment in the advanced unresectable or metastatic setting\n\nKey Exclusion Criteria:\n\n* Known EGFR, KRAS, NRAS, HRAS, or BRAF oncogenic-driver co-mutation with PI3K\u002FAKT\u002FPTEN alteration\n* Clinically significant abnormalities of glucose metabolism\n* Active brain metastases or carcinomatous meningitis.\n* History of significant hemoptysis or hemorrhage within 4 weeks prior to first dose of study drug\n* Malabsorption syndrome, nausea and vomiting uncontrolled by medication, or disease significantly affecting gastrointestinal function likely to interfere with the delivery, absorption, or metabolism of TER-2013\n* Prior therapy:\n\n  1. \\[For TER-2013 monotherapy escalation\\]: AKT inhibitor\n  2. \\[For TER-2013 monotherapy expansion\\]: AKT\u002FPI3K\u002FPTEN pathway inhibitor\n  3. \\[For TER-2013 + fulvestrant combination expansion\\]: AKT\u002FPI3K\u002FPTEN pathway inhibitor, fulvestrant and other SERDs, mTOR inhibitor; some PIK3CA-altered cohorts allow prior PI3K inhibitor.\n\nOther protocol-defined Inclusion\u002FExclusion Criteria apply","ALL","18 Years",{"count":305,"type":306},205,"ESTIMATED","INTERVENTIONAL",[309,310],"PHASE1","PHASE2","This is a Phase 1\u002F2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT\u002FPI3K\u002FPTEN pathway alterations.",[313,314,315,316,317,318,319,320],"Breast Cancer","Endometrial Cancer","Ovarian Cancer","Lung Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma","Esophageal Squamous Cell Carcinoma","Solid Tumor","Cervical Cancer",[322,313,323,324],"AKT\u002FPI3K\u002FPTEN Alterations","Advanced Solid Tumors","HR+\u002FHER2-","2026-08-19",{"date":327,"type":328},"2026-08-21","ACTUAL",{"date":330,"type":328},"2025-09-23",{"date":332,"type":306},"2029-02-28",{"name":5,"class":6},18]